Navigation Links
New venture explores frontiers of personalized medicine
Date:10/26/2010

Pharmaceuticals that seek out cancerous cells and deliver treatments to them; imaging techniques that can help doctors detect diseases before the physical signs begin to appear; and medicines that are tailor-made for individual patients, are within the sights of an exciting new Australian start-up venture.

Clarity Pharmaceuticals Pty Ltd is a new venture, which could lead to a revolution in the future of medical diagnosis and treatment.

To launch the company, Clarity has secured licences to technology developed by the University of Melbourne and the Australian Nuclear Science and Technology Organisation (ANSTO).

Dr Matt Harris, Managing Director of TM Ventures says the basis of Clarity Pharmaceuticals is exciting new compounds developed by scientists from ANSTO and the University of Melbourne for use in positron emission tomography (PET).

"PET is the fastest growing nuclear medicine modality. Whilst tests such as X-ray and MRI provide information on anatomy and structure, PET uses the movement of radiopharmaceuticals through the body to examine metabolic processes, such as heart and brain function in real time," he said.

"Based on foundational research undertaken by the University of Melbourne and ANSTO, Clarity Pharmaceuticals is the future of personalised medicine."

Research teams from both the University of Melbourne and ANSTO have developed new compounds that significantly improve the accuracy of PET imaging.

These compounds can also be used in treatment to target therapeutics to specific disease sites and then to accurately monitor how well that treatment is working.

"These agents are targeted to selectively illuminate diseased tissue. The new compounds have the potential to provide clinicians with valuable diagnostic information to guide, improve and assess treatment regimes," said Dr Paul Donnelly from the University of Melbourne's School of Chemistry.

"Using PET images, doctors will have the potential to improve diagnosis and provide a personal prognosis. Ongoing monitoring using PET will determine progress and enable the refining of treatment options," he said.

According to ANSTO General Manager of Business Development, Rosanne Robinson, this exciting venture will enable even wider community accessibility to PET technology with great outcomes.

"For patients with cancer, this treatment could be revolutionary. No longer would patients suffer from the terrible side effects of chemotherapy because treatment could be precise, targeted and effective," she said.

In addition, the high calibre of research from which Clarity Pharmaceuticals has been founded, was acknowledged by the Victorian Government through the awarding of a Victoria Fellowship to a member of Dr Donnelly's research team, Dr Michelle Ma.


'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Related medicine news :

1. Online Deals on Golf, now in Full Swing at GolfAdventures.com
2. Win A Trip To New Zealand For Four: The Great Kiwi Adventure and ZESPRI's Kiwi A-Go-Go Bloggers' Contest
3. Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex
4. Bold Ventures Launches New Healthcare Business
5. Kid Structures Prepares Houston's Beach Family for New Adventures
6. Iowan Tackles Everest and More in Unprecedented Adventure
7. Restless Josie, an Internet Adventure Travel Show, Empowers and Enlightens!
8. PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest
9. 15 Free Videos, Kids Visit GarGar The Dentist, Promote Children's Oral Health Education - MouthWise Web Adventures 4 Kids.
10. Forest City Announces Joint Venture with Health Care REIT for University Park Life Science Properties
11. Travel to 10 Best Eco-Adventure Destinations in India with Thrillophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, ... in its IT Advisory Services practice . Rossi is the third technology consulting ... for strategic IT guidance grows, and the practice continues to expand.     , Bringing more ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ago the ... Education program forged a relationship built upon the foundation of sports safety. ... of both student members and certified members of the Athletic Trainers’ Society of ...
(Date:1/16/2017)... ... January 16, 2017 , ... Gym Source, America’s leading retailer of premium ... East Hanover, New Jersey. , “We are elated to be opening this new showroom,” ... is designed to give clients a seamless and motivating shopping experience.” , Every fitness ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... office , Antoine Dental Center, is currently offering complimentary consultations and financing for ... their teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , January 17, 2017 ... 2016;11(Suppl. 1):2-4 ; http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ... ... Published recently in European Neurological ... touchNEUROLOGY, Catherine Amey reports that despite ...
(Date:1/17/2017)... -- Transparency Market Research has released a new market ... Alcohol and Others) Market - Global Industry Analysis, Size, Share, Growth, ... benzaldehyde derivative market was valued at US$ 1.37 Bn in ... expanding at a CAGR of 5.1 % from 2016 to 2024. ... Benzaldehyde derivatives are ...
(Date:1/17/2017)... BUDAPEST, Hungary , Jan. 17, 2017 /PRNewswire/ ... Plc. today announced positive results from Venus II, the second ... and safety of ulipristal acetate in women with abnormal bleeding ... ulipristal acetate is planned for the second half of 2017. ... Venus II supporting the efficacy and safety profile of ulipristal ...
Breaking Medicine Technology: